Key stats
About Range Cancer Therapeutics ETF
Expense ratio
0.79%
Home page
Inception date
Oct 13, 2015
ISIN
US26922A8264
CNCR takes an approach to niche coverage within the health care sector. It provides equal-weighted exposure to companies that generate their revenue from oncology products or are in constant development and production of cancer therapeutic medicine. Cancer Therapeutics is a term used to refer to the wide range of treatments and interventions used to treat the various kinds of cancer. Its goal is to eliminate or control the disease while also aiming to minimize the damage done to healthy cells and tissues. Equal-weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space. Prior to June 20, 2023, the fund tracked the Loncar Cancer Immunotherapy Index and traded under the name Loncar Cancer Immunotherapy ETF. Effective October 20, 2023, the Loncar China BioPharma ETF that traded under the symbol CHNA merged into CNCR, acquiring its assets and expanding the funds exposure to China.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region